CN1925859B - 用于治疗焦虑、抑郁和癫痫的作为gaba受体配体的4-(硫基-嘧啶-4-基甲基)-吗啉衍生物和相关的化合物 - Google Patents
用于治疗焦虑、抑郁和癫痫的作为gaba受体配体的4-(硫基-嘧啶-4-基甲基)-吗啉衍生物和相关的化合物 Download PDFInfo
- Publication number
- CN1925859B CN1925859B CN2005800066192A CN200580006619A CN1925859B CN 1925859 B CN1925859 B CN 1925859B CN 2005800066192 A CN2005800066192 A CN 2005800066192A CN 200580006619 A CN200580006619 A CN 200580006619A CN 1925859 B CN1925859 B CN 1925859B
- Authority
- CN
- China
- Prior art keywords
- compound
- methyl
- formula
- ylmethyl
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04100830 | 2004-03-02 | ||
| EP04100830.1 | 2004-03-02 | ||
| PCT/EP2005/001814 WO2005094828A1 (en) | 2004-03-02 | 2005-02-22 | 4- (sulfanyl-pyrimidin-4-ylmethyl) -morpholine derivatives and related compounds as gaba receptor ligands for the treatment of anxiety, depression and epilepsy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1925859A CN1925859A (zh) | 2007-03-07 |
| CN1925859B true CN1925859B (zh) | 2010-11-24 |
Family
ID=34896109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005800066192A Expired - Fee Related CN1925859B (zh) | 2004-03-02 | 2005-02-22 | 用于治疗焦虑、抑郁和癫痫的作为gaba受体配体的4-(硫基-嘧啶-4-基甲基)-吗啉衍生物和相关的化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7351700B2 (https=) |
| EP (1) | EP1725239B1 (https=) |
| JP (1) | JP4563447B2 (https=) |
| KR (1) | KR100802863B1 (https=) |
| CN (1) | CN1925859B (https=) |
| AT (1) | ATE367163T1 (https=) |
| AU (1) | AU2005229505B2 (https=) |
| BR (1) | BRPI0508310A (https=) |
| CA (1) | CA2557719A1 (https=) |
| DE (1) | DE602005001696T2 (https=) |
| ES (1) | ES2290885T3 (https=) |
| PL (1) | PL1725239T3 (https=) |
| RU (1) | RU2382033C2 (https=) |
| WO (1) | WO2005094828A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2353619C2 (ru) | 2007-06-28 | 2009-04-27 | Общество С Ограниченной Ответственностью "Бионика" | Новые соединения, обладающие функцией антикоагулянтов, фармацевтические композиции на их основе для лечения тромботических состояний и плазмозамещающий раствор для коррекции гиперкоагуляционных нарушений при гемодилюции |
| RU2354647C2 (ru) * | 2007-06-28 | 2009-05-10 | Общество С Ограниченной Ответственностью "Бионика" | Новые соединения, обладающие функцией ингибиторов тромбина, и фармацевтические композиции на их основе |
| CA2692945A1 (en) * | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Compounds - 945 |
| TW201623257A (zh) | 2014-05-09 | 2016-07-01 | 奧利安公司 | 藥理活性之喹唑啉二酮衍生物 |
| KR102269132B1 (ko) | 2014-06-10 | 2021-06-25 | 삼성디스플레이 주식회사 | 반방향족성 화합물 및 이를 포함하는 유기 발광 소자 |
| US10084141B2 (en) | 2014-06-13 | 2018-09-25 | Samsung Display Co., Ltd. | Antiaromatic compound and organic light-emitting device including the same |
| HU231058B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt. | Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| TWI907472B (zh) | 2020-08-05 | 2025-12-11 | 匈牙利商羅特格登公司 | 具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物 |
| GB202414197D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202414199D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel Compounds |
| GB202414200D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202414193D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202414192D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1142817A (zh) * | 1993-10-12 | 1997-02-12 | 杜邦麦克制药有限公司 | 1n-烷基-n-芳基嘧啶胺及其衍生物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| WO2001056990A2 (en) | 2000-02-03 | 2001-08-09 | Eli Lilly And Company | Pyridine derivates as potentiators of glutamate receptors |
| CA2444148A1 (en) * | 2001-04-11 | 2002-10-24 | Queen's University At Kingston | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents |
| GB0209481D0 (en) | 2002-04-24 | 2002-06-05 | Novartis Ag | Organic compounds |
-
2005
- 2005-02-22 KR KR1020067017683A patent/KR100802863B1/ko not_active Expired - Fee Related
- 2005-02-22 AT AT05707562T patent/ATE367163T1/de active
- 2005-02-22 AU AU2005229505A patent/AU2005229505B2/en not_active Ceased
- 2005-02-22 CN CN2005800066192A patent/CN1925859B/zh not_active Expired - Fee Related
- 2005-02-22 CA CA002557719A patent/CA2557719A1/en not_active Abandoned
- 2005-02-22 JP JP2007501167A patent/JP4563447B2/ja not_active Expired - Fee Related
- 2005-02-22 WO PCT/EP2005/001814 patent/WO2005094828A1/en not_active Ceased
- 2005-02-22 DE DE602005001696T patent/DE602005001696T2/de not_active Expired - Lifetime
- 2005-02-22 BR BRPI0508310-9A patent/BRPI0508310A/pt not_active IP Right Cessation
- 2005-02-22 PL PL05707562T patent/PL1725239T3/pl unknown
- 2005-02-22 EP EP05707562A patent/EP1725239B1/en not_active Expired - Lifetime
- 2005-02-22 ES ES05707562T patent/ES2290885T3/es not_active Expired - Lifetime
- 2005-02-22 RU RU2006134632/04A patent/RU2382033C2/ru not_active IP Right Cessation
- 2005-02-23 US US11/064,046 patent/US7351700B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1142817A (zh) * | 1993-10-12 | 1997-02-12 | 杜邦麦克制药有限公司 | 1n-烷基-n-芳基嘧啶胺及其衍生物 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100802863B1 (ko) | 2008-02-12 |
| WO2005094828A1 (en) | 2005-10-13 |
| KR20060116240A (ko) | 2006-11-14 |
| EP1725239B1 (en) | 2007-07-18 |
| RU2006134632A (ru) | 2008-04-10 |
| EP1725239A1 (en) | 2006-11-29 |
| DE602005001696D1 (de) | 2007-08-30 |
| US20050197337A1 (en) | 2005-09-08 |
| AU2005229505A1 (en) | 2005-10-13 |
| AU2005229505B2 (en) | 2010-07-15 |
| BRPI0508310A (pt) | 2007-07-24 |
| DE602005001696T2 (de) | 2008-04-10 |
| CA2557719A1 (en) | 2005-10-13 |
| JP4563447B2 (ja) | 2010-10-13 |
| PL1725239T3 (pl) | 2007-12-31 |
| ES2290885T3 (es) | 2008-02-16 |
| US7351700B2 (en) | 2008-04-01 |
| JP2007526266A (ja) | 2007-09-13 |
| CN1925859A (zh) | 2007-03-07 |
| RU2382033C2 (ru) | 2010-02-20 |
| ATE367163T1 (de) | 2007-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1925859B (zh) | 用于治疗焦虑、抑郁和癫痫的作为gaba受体配体的4-(硫基-嘧啶-4-基甲基)-吗啉衍生物和相关的化合物 | |
| KR100912145B1 (ko) | Ｇａｂａ-ｂ 알로스테릭성 개선제로서 티에노-피리딘유도체 | |
| CN105814022B (zh) | 作为tnf活性调节剂的稠合的二环杂芳族衍生物 | |
| CN107286174B (zh) | 取代2,4-(1h,3h)嘧啶二酮作为parp抑制剂及其应用 | |
| US20060094879A1 (en) | New indolylpiperidine derivatives as potent antihistaminic and antiallergic agents | |
| DE68926553T2 (de) | Lactamderivate | |
| CN101605792A (zh) | 氮杂-异吲哚酮和它们作为亲代谢性谷氨酸受体增效剂-613的用途 | |
| CN101484424A (zh) | 治疗化合物 | |
| EP2438067A1 (de) | Neue verbindungen | |
| TW201345908A (zh) | 吡唑并〔１，５-ａ〕嘧啶化合物 | |
| TW200936570A (en) | 2-aminopyrimidine derivatives | |
| HRP980319A2 (en) | 3-substituted 3,4-dihydro-thieno/2,3-d/pyrimidine derivatives, their preparation and use | |
| JPWO2017026516A1 (ja) | イソチアゾール誘導体 | |
| CN1989113B (zh) | 喹唑啉衍生物 | |
| TW200835495A (en) | Substituted 8-piperidinyl-2-pyridinyl-pyrimido[1,2-a] pyrimidin-6-one and 8-piperidinyl-2-pyrimidinyl-pyrimido[1,2-a] pyrimidin-6-one derivatives | |
| DE69829317T2 (de) | Tetrahydrobenzindol-derivate | |
| TW200808779A (en) | Novel compound | |
| IL301717B1 (en) | Tetrazole derivatives as trpa1 inhibitors | |
| JP2001512734A (ja) | ３−置換３，４，５，７−テトラヒドロピロロ［３’，４’：４，５］−チエノ［２，３−ｄ］ピリミジン誘導体、その製造方法および５ＨＴ拮抗薬としての使用 | |
| JP6124154B2 (ja) | 置換ピラゾロ［１，５−ａ］ピリジン、その製造方法及び薬剤としての使用 | |
| KR20160003752A (ko) | 피라지노[1,2-a]인돌 화합물들, 그들의 제조 및 의약에서의 이용 | |
| JP2021512942A (ja) | トリアゾール、イミダゾールおよびピロール縮合ピペラジン誘導体、およびｍＧｌｕ５受容体のモジュレータとしてのそれらの使用 | |
| CN101597260A (zh) | 新的毒蕈碱受体拮抗剂及其用途 | |
| MXPA06009949A (es) | Derivados 4-(sulfanil-pirimidin-4-ilmetil)-morfolina y compuestos relacionados como ligandos del receptor gaba para el tratamiento contra ansiedad, depresion y epilepsia | |
| PT780388E (pt) | Ligandos de 5ht1dalfa e 5ht2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101124 Termination date: 20120222 |